Baseline demographic and clinical characteristics of each study group
| Characteristics . | Metformin . | . | Placebo . | . | ||
|---|---|---|---|---|---|---|
| . | Run in . | Randomization . | Run in . | Randomization . | ||
| n | 14 | 13 | ||||
| Age (years) | 15.7 ± 1.9 | 15.9 ± 1.9 | 15.9 ± 1.7 | 16 ± 1.7 | ||
| Sex (F/M) | 8/6 | 6/7 | ||||
| Duration of diabetes (years) | 9.7 ± 4.4 | 9.9 ± 4.4 | 6.9 ± 3.8 | 7 ± 3.8 | ||
| Weight (kg) | 62.9 ± 13.7 | 63.3 ± 13.6 | 71.2 ± 11.7 | 71.6 ± 11.7 | ||
| BMI (kg/m2) | 22.7 ± 4.1 | 22.8 ± 4.2 | 25.4 ± 2.9 | 25.7 ± 2.9 | ||
| Pubertal status (Tanner2–3/Tanner4–5) | 5/9 | 5/8 | ||||
| HbA1c (%) | 9.4 ± 1 | 9.3 ± 1.4 | 8.9 ± 0.8 | 8.6 ± 0.8 | ||
| Insulin dosage (units · kg−1 · day−1) | 1.2 ± 0.2 | 1.21 ± 0.3 | 1.3 ± 0.2 | 1.28 ± 0.19 | ||
| SI (× 10−4 · min−1 · μU−1 · ml−1) | 1.7 (CI 1.0–2.6) | 1.1 (CI 0.6–2.2) | ||||
| Characteristics . | Metformin . | . | Placebo . | . | ||
|---|---|---|---|---|---|---|
| . | Run in . | Randomization . | Run in . | Randomization . | ||
| n | 14 | 13 | ||||
| Age (years) | 15.7 ± 1.9 | 15.9 ± 1.9 | 15.9 ± 1.7 | 16 ± 1.7 | ||
| Sex (F/M) | 8/6 | 6/7 | ||||
| Duration of diabetes (years) | 9.7 ± 4.4 | 9.9 ± 4.4 | 6.9 ± 3.8 | 7 ± 3.8 | ||
| Weight (kg) | 62.9 ± 13.7 | 63.3 ± 13.6 | 71.2 ± 11.7 | 71.6 ± 11.7 | ||
| BMI (kg/m2) | 22.7 ± 4.1 | 22.8 ± 4.2 | 25.4 ± 2.9 | 25.7 ± 2.9 | ||
| Pubertal status (Tanner2–3/Tanner4–5) | 5/9 | 5/8 | ||||
| HbA1c (%) | 9.4 ± 1 | 9.3 ± 1.4 | 8.9 ± 0.8 | 8.6 ± 0.8 | ||
| Insulin dosage (units · kg−1 · day−1) | 1.2 ± 0.2 | 1.21 ± 0.3 | 1.3 ± 0.2 | 1.28 ± 0.19 | ||
| SI (× 10−4 · min−1 · μU−1 · ml−1) | 1.7 (CI 1.0–2.6) | 1.1 (CI 0.6–2.2) | ||||
Data are means ± SD, except SI, which is expressed as geometric mean and 95% CI.